Study guide

2.3 Disease Prevention, Lifestyle Counselling, & Harm Reduction

Medical Council of Canada Qualifying Examination Part I MCCQE Part I

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview, Blueprint & Canadian Medical Practice

1.1 MCCQE Part I Format, Scoring (439 Scale), & Strategy 1.2 The MCC Blueprint Matrix: Dimensions of Care & Physician Activities 1.3 Canadian Healthcare System, CanMEDS Roles, & Interprofessional Care 1.4 Evidence-Based Medicine, Study Design, & Clinical Statistics

2 Chapter 2: Population Health, Health Promotion & Preventive Care

2.1 Canadian Task Force on Preventive Health Care (CTFPHC) Screening Guidelines 2.2 Immunization Schedules (NACI) & Vaccine-Preventable Diseases across Lifespan 2.3 Disease Prevention, Lifestyle Counselling, & Harm Reduction 2.4 Outbreak Management, Disease Surveillance, & Infection Control 2.5 Occupational, Environmental, & Travel Medicine in Canada

3 Chapter 3: Internal Medicine — Cardiovascular & Respiratory Systems

3.1 Hypertension Canada 2020/2025 Guidelines, Dyslipidemia, & Primary Prevention 3.2 Ischemic Heart Disease, Acute Coronary Syndromes, & Heart Failure Management 3.3 Arrhythmias, Valvular Heart Disease, & Infective Endocarditis 3.4 Asthma, COPD, & Respiratory Failure (CTS Guidelines) 3.5 Thromboembolic Disease (DVT/PE), Pneumonia, & Pleural Effusions

4 Chapter 4: Internal Medicine — GI, Endocrine, Renal & Hematology/Oncology

4.1 Gastrointestinal Disorders, Acute Abdomen, & Liver/Biliary Disease 4.2 Diabetes Canada 2020/2025 Guidelines & Glycemic Management 4.3 Thyroid, Adrenal, Pituitary, & Electrolyte Disturbances 4.4 Acute Kidney Injury (AKI), Chronic Kidney Disease (CKD), & Nephrology 4.5 Hematology, Anemia Evaluation, Transfusion Medicine, & Common Cancers

5 Chapter 5: General Surgery, Orthopedics, & Emergency Care

5.1 Surgical Evaluation, Preoperative Clearance, & Postoperative Complications 5.2 Trauma Management (ATLS Protocol) & Burns 5.3 Acute Surgical Conditions (Appendicitis, Cholecystitis, Bowel Obstruction) 5.4 Fractures, Dislocations, Joint Pain, & Musculoskeletal Emergencies 5.5 Vascular Emergencies, Wound Care, & Shock Recognition

6 Chapter 6: Pediatrics & Adolescent Health

6.1 Pediatric Growth, Developmental Milestones, & Well-Child Examinations 6.2 Neonatal Resuscitation, Jaundice, & Common Congenital Anomalies 6.3 Pediatric Respiratory Emergencies (Croup, Bronchiolitis, Asthma) 6.4 Common Pediatric Infections, Exanthems, & Fever of Unknown Origin 6.5 Pediatric Abdominal Pain, Dehydration, & Fluid Management

7 Chapter 7: Obstetrics & Gynecology

7.1 Routine Antepartum Care, Screening, & Prenatal Diagnosis (SOGC Guidelines) 7.2 Medical Complications of Pregnancy (Preeclampsia, Gestational Diabetes, Infections) 7.3 Labor, Intrapartum Management, & Postpartum Complications/Hemorrhage 7.4 Abnormal Uterine Bleeding, Gynecologic Infections, & Contraception/Menopause 7.5 Gynecologic Oncology & Pelvic Mass Evaluation

8 Chapter 8: Psychiatry & Mental Health

8.1 Mood Disorders (Depression, Bipolar) & Suicide Risk Assessment 8.2 Anxiety Disorders, OCD, PTSD, & Somatic Symptom Disorders 8.3 Psychotic Disorders & Schizophrenia Management 8.4 Substance Use Disorders, Withdrawal Syndromes, & Harm Reduction 8.5 Pediatric, Perinatal, & Geriatric Psychiatry (Cognitive Impairment / Delirium)

9 Chapter 9: Neurology, Rheumatology, & Dermatology

9.1 Acute Stroke, TIA, & Neurovascular Emergencies 9.2 Headaches, Seizures, Movement Disorders, & Neuromuscular Disease 9.3 Inflammatory Arthritides (RA, Gout, SpA) & Systemic Autoimmune Diseases (SLE, Vasculitis) 9.4 Common Dermatologic Conditions, Cutaneous Manifestations of Systemic Disease, & Skin Cancers 9.5 Musculoskeletal Soft Tissue Injuries, Back Pain, & Physical Medicine

10 Chapter 10: Legal, Ethical, & Professional Behaviours in Canadian Practice

10.1 Informed Consent, Capacity Assessment, & Substitute Decision-Making (CMPA) 10.2 Medical Confidentiality, Privacy Laws (PIPEDA/PHIPA), & Disclosure of Harm 10.3 CMA Code of Ethics, Professionalism, & Physician Health/Boundary Issues 10.4 Mandatory Reporting (Child/Elder Abuse, Driving Safety, Fitness to Practice) & Quality/Safety

2.3 Disease Prevention, Lifestyle Counselling, & Harm Reduction

Key Takeaways Explain This Topic AI

Prevention operates across four distinct levels: Primary (preventing onset), Secondary (screening asymptomatic disease), Tertiary (managing established disease), and Quaternary (protecting from medicalization/overtreatment).

Smoking cessation counseling relies on the 5 As framework; Varenicline or combination NRT are most effective, while Bupropion is strictly contraindicated in patients with seizure or eating disorders.

Canada's Guidance on Alcohol and Health (2023) defines a continuum of risk: 0 drinks/week (no risk), 1–2 (low risk), 3–6 (moderate risk), and 7+ (increasingly high risk).

Harm reduction interventions (naloxone distribution, supervised consumption, needle exchanges, opioid agonist therapy) reduce substance-related morbidity and mortality without mandating total abstinence.

Buprenorphine-naloxone (Suboxone) is the preferred first-line Opioid Agonist Therapy (OAT) in Canada due to its favorable safety profile and lower overdose risk compared to Methadone.

Last updated: July 2026

Disease Prevention, Lifestyle Counselling, & Harm Reduction

Health promotion and disease prevention form the foundation of preventive medicine in Canadian healthcare. Physicians must master the four levels of prevention , evidence-based lifestyle counseling, and pragmatic harm reduction strategies for substance use disorders.

The Four Levels of Disease Prevention

Preventive care is classified into four distinct levels based on the stage of disease and the objective of the intervention.

Definitions & Clinical Examples

Primary Prevention: Actions aimed at preventing the initial occurrence of a disease or injury in a healthy population.

Examples: Routine pediatric immunizations, public health legislation (seatbelt/helmet laws), workplace safety regulations, counseling for smoking prevention, fluoridation of municipal drinking water.

Secondary Prevention: Early detection and prompt management of asymptomatic disease or precursor lesions before clinical symptoms manifest.

Examples: Mammography, Pap tests, FIT stool testing, routine screening blood pressure measurements, screening for asymptomatic Chlamydia/Gonorrhea.

Tertiary Prevention: Clinical interventions designed to slow disease progression, prevent complications, reduce disability, and rehabilitate patients with established symptomatic clinical disease.

Examples: Cardiac rehabilitation post-myocardial infarction, tight glycemic and blood pressure control in Type 2 Diabetes to prevent nephropathy and retinopathy, physical therapy following a cerebrovascular accident (stroke).

Quaternary Prevention: Actions taken to identify patients at risk of overmedicalization, protecting them from unnecessary diagnostic procedures, overdiagnosis, unproven therapies, and ethical/procedural medical harms.

Examples: Refusing routine lumbar spine X-rays for acute simple low back pain without red flags, deprescribing inappropriate polypharmacy in elderly patients, advising against routine PSA screening in average-risk asymptomatic men.

Tobacco Cessation & Pharmacotherapy

Tobacco use remains the leading cause of preventable morbidity and premature mortality in Canada. Primary care physicians should systematically apply the 5 As Framework for smoking cessation:

Ask: Identify and document tobacco use status for every patient at every visit.

Advise: Strongly urge all tobacco users to quit in a clear, non-judgmental, personalized manner.

Assess: Determine readiness to make a quit attempt (Transtheoretical Model / Stages of Change).

Assist: Aid the patient in quitting (counseling, setting a quit date, prescribing pharmacotherapy).

Arrange: Schedule follow-up contact within the first week after the quit date.

Pharmacotherapy Comparison

Medication Mechanism of Action Clinical Efficacy & Dosage Contraindications & Key Precautions

Nicotine Replacement Therapy (NRT) Provides clean nicotine to reduce withdrawal symptoms Transdermal patch (long-acting) combined with gum/lozenge/inhaler (short-acting). Combination NRT is superior to monotherapy. Acute coronary syndrome within 2 weeks, severe unmanaged arrhythmias, severe angina

Varenicline Partial agonist at α4β2 nicotinic acetylcholine receptors Highest monotherapy efficacy. Reduces cravings and blocks rewarding effects of smoking. Dose-adjust in severe renal impairment (CrCl <30 mL/min). Side effects: nausea, vivid dreams, insomnia

Bupropion SR Norepinephrine-dopamine reuptake inhibitor (NDRI) Effective monotherapy; reduces craving and post-cessation weight gain. STRICTLY CONTRAINDICATED in: ; 1. Seizure disorders; 2. Current/past Anorexia Nervosa or Bulimia Nervosa; 3. Abrupt alcohol/sedative withdrawal; 4. Concurrent MAOI use

  • Alcohol Guidance & Substance Harm Reduction
  • Canada's Guidance on Alcohol and Health (2023 Update)

Published by the Canadian Centre on Substance Use and Addiction (CCSA), this framework defines a continuum of risk associated with weekly standard drink consumption (1 standard drink = 12 oz / 341 mL 5% beer, 5 oz / 142 mL 12% wine, or 1.5 oz / 43 mL 40% spirits):

0 Drinks per week: No risk; best health outcomes, especially during pregnancy or breastfeeding.

1 to 2 Standard Drinks per week: Low risk of alcohol-related harms.

3 to 6 Standard Drinks per week: Moderate risk ; increased risk of developing several types of cancer (breast, colorectal).

7 or more Standard Drinks per week: Increasingly high risk ; exponentially higher risk of cardiovascular disease, stroke, liver cirrhosis, and violent injury.

Harm Reduction Principles & Opioid Use Disorder

Harm reduction encompasses evidence-informed public health policies and pragmatic interventions designed to minimize the adverse health, social, and economic consequences of substance use without requiring complete abstinence.

Take-Home Naloxone (THN) Kits: Widespread distribution of intranasal or intramuscular naloxone to individuals who use opioids, their families, and community members for rapid reversal of opioid toxicity.

Supervised Consumption Services (SCS) & Overdose Prevention Sites (OPS): Medically supervised facilities providing sterile consumption equipment, emergency overdose intervention, wound care, STI screening, and direct referral pathways to addiction treatment.

Needle & Syringe Programs (NSP): Provision of sterile injection and inhalation supplies to prevent transmission of blood-borne pathogens (HIV, Hepatitis B, Hepatitis C).

Opioid Agonist Therapy (OAT):

Buprenorphine-Naloxone (Suboxone): First-line OAT in Canada. Partial mu-opioid agonist with high receptor affinity and a safety "ceiling effect" on respiratory depression. Combined with naloxone to deter intravenous misuse.

Methadone: Second-line OAT. Full mu-opioid agonist requiring daily witnessed pharmacy ingestion. Requires strict monitoring for QTc prolongation, drug interactions, and fatal overdose during dose titration.

Lifestyle Counseling: Nutrition, Movement & Sleep

Canada's Food Guide: Emphasizes healthy eating habits rather than rigid food groups. Recommended plate model: 1/2 vegetables and fruits , 1/4 protein foods (emphasizing plant-based proteins such as beans, lentils, nuts), and 1/4 whole grain foods . Water should be the beverage of choice.

Canadian 24-Hour Movement Guidelines (Adults 18–64 Years):

Physical Activity: Accumulate at least 150 minutes per week of moderate-to-vigorous aerobic physical activity.

Muscle Strengthening: Incorporate muscle-strengthening activities involving major muscle groups at least 2 days per week .

Sleep: Maintain 7 to 9 hours of good-quality sleep per night with consistent sleep-wake timing.

Sedentary Behavior: Limit sedentary time to 8 hours or less per day , including no more than 3 hours of recreational screen time.

Exam Trap: Bupropion is a common MCCQE Part I trap. If a patient seeking smoking cessation has a history of anorexia nervosa, bulimia nervosa, or seizures , Bupropion is strictly contraindicated . Select Varenicline or Nicotine Replacement Therapy instead.

Clinical Scenario: A 34-year-old man with severe Opioid Use Disorder presents seeking treatment. He has experienced two non-fatal respiratory overdoses in the past year. What is the most appropriate first-line pharmacotherapy to initiate in Canada?

Answer: Buprenorphine-naloxone (Suboxone). Suboxone is recommended as the first-line Opioid Agonist Therapy (OAT) in Canadian guidelines because its partial agonist mechanism provides a safety ceiling against respiratory depression, significantly reducing overdose mortality compared to Methadone.

Loading diagram... Transtheoretical Model (Stages of Change) for Lifestyle Counseling